Indoco Remedies Limited Files Business Responsibility and Sustainability Report for FY2025-26
Indoco Remedies Limited filed its BRSR for FY2025-26. The report details operations, ESG targets, and sustainability initiatives. Key achievements include a 43.5% renewable energy mix and an 18.6% reduction in Scope 1 emissions. The company aims for a 3% reduction in freshwater, energy, and GHG emissions by 2030.
The filing of a Business Responsibility and Sustainability Report is a regulatory requirement and a standard disclosure for listed companies. It does not typically have a direct, immediate financial impact on the company's stock price or operations.
The announcement is a routine filing of the Business Responsibility and Sustainability Report, providing detailed disclosures on ESG practices and targets. While it highlights positive initiatives and achievements, it does not contain significant new financial information or strategic shifts that would warrant a positive or negative sentiment.
Indoco Remedies Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the financial year 2025-2026. This report, prepared on a standalone basis, details the company's commitment to ethical and sustainable business practices.
The report covers various aspects of the company's operations, including its business activities, products, market reach, and employee details. Indoco Remedies Limited emphasizes its manufacturing of formulation pharmaceuticals, with 89% of its turnover coming from formulation pharmaceutical preparations and 9% from Active Pharmaceutical Ingredients. The company serves 20 states nationally and exports to over 55 countries, with exports contributing 45.10% of its total standalone revenue.
The company has detailed its workforce, comprising 5,038 employees and 1,517 workers, with a focus on diversity and inclusion, noting 25% female representation on its Board of Directors. It also highlights its CSR activities and has a robust grievance redressal mechanism in place for various stakeholders, including investors, employees, and customers.
Key disclosures include the company's approach to material ESG issues such as energy management, carbon emissions, water management, waste management, and social responsibility. Indoco Remedies Limited has set specific ESG targets for 2030, aiming to reduce freshwater withdrawal, energy consumption, and Scope 1 & 2 GHG emissions by 3% each, using FY2025-26 as the baseline. The company reported a significant increase in renewable energy usage to 43.5% and a reduction in Scope 1 emissions by 18.6% in FY2025-26.
Furthermore, the report outlines the company's policies and processes related to business integrity, product safety, and supply chain management. Indoco Remedies Limited has an anti-corruption and anti-bribery policy and reports zero incidents of corruption or bribery involving directors, KMPs, employees, or workers for FY2025-26 and FY2024-25. The company also details its waste management procedures for plastics, e-waste, hazardous waste, and other waste, adhering to regulatory requirements and prioritizing recycling and safe disposal.
What to do with a filing like this
Indoco Remedies Limited filed this with the NSE as a statutory disclosure, categorised under business responsibility and sustainability report (brsr). It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Indoco Remedies Limited. Read the original for the full detail.